Author(s):
1. Aisha Iram Mohsin:
RAK Medical and Health Science University Ras al Kamiah, UAE
2. Saima Javaid:
RAK Medical and Health Science University Ras al Kamiah, UAE
3. Maryam Mehwish:
RAK Medical and Health Science University Ras al Kamiah, UAE
4. Rangraze Imran:
RAK Medical and Health Science University Ras al Kamiah, UAE
Abstract:
The COVID-19 disease, which is caused by the coronavirus, SARS-COV2 had affected the world in 2020 causing a high mortality and morbidity in affected patients. Numerous clinical studies performed worldwide have demonstrated the great potential of MSCs used to prevent complications caused by COVID. In this review, we focus on the potency of mesenchymal stem cell (MSCs) for treating critically ill patients at the risk of developing permanent lung damage and discussed the aspects of this proposed treatment using reported clinical trials and hypotheses.
Page(s):
2250-2255
DOI:
DOI not available
Published:
Journal: Bioscience Research, Volume: 19, Issue: 4, Year: 2022
Keywords:
SARS CoV2
,
COVID19
,
Mesenchymal stem cell therapy
References:
References are not available for this document.
Citations
Citations are not available for this document.